Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenxian Zhou has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Attenuation of Cardiac Dysfunction in the Collagen-Induced Arthritis Mouse Model Mediated by a Reactive Aldehyde Species Inhibitor

    by Wenxian Zhou, Hannah J. Johnson, Michael J. Duryee, Ali Namvaran, Aradhana Thapa, Cole Blasing, Amy Nelson, Engle E. Sharp, Carlos D. Hunter, Bryan Hackfort, et al.

    Individuals with rheumatoid arthritis (RA) experience increased risk of heart failure. Malondialdehyde–acetaldehyde (MAA) adducts are overexpressed and co-localize with citrullinated (CIT) proteins in RA myocardium. This study investigated whether reactive aldehyde species (RASP) inhibitors prevent MAA formation in vitro and attenuate cardiac dysfunction in a collagen-induced arthritis (CIA) mouse model. Among eight RASP inhibitors screened, ADX-246 demonstrated the greatest inhibition of MAA formation in vitro. Mice with early CIA (week 5) exhibited elevated levels of myocardial MAA adducts, myocardial inflammation, and reduced ejection fraction, but normal cardiac collagen deposition and diastolic function vs. control. By weeks 10–12, mice with chronic CIA demonstrated increased levels of myocardial MAA and CIT adducts, perivascular collagen deposition, and diastolic dysfunction. ADX-246 treatment reduced myocardial levels of MAA and CIT adducts, inflammation, fibrosis, and cardiac dysfunction in CIA. While ADX-246 reduced weight loss and attenuated arthritis severity, it did not reduce serum autoantibody levels or serum markers of inflammation or fibrosis. Indices of diastolic dysfunction significantly correlated with myocardial MAA and CIT levels, collagen deposition, arthritis severity, and weight loss. These findings support the hypothesis that targeting myocardial RASP and MAA formation may represent a novel therapeutic approach for preventing cardiac dysfunction in RA.

  • Open Access

    Malondialdehyde-acetaldehyde modified macromolecules and resulting autoantibodies in rheumatoid arthritis pathogenesis: a Systematic Literature Review

    by Wenxian Zhou, Nozima Aripova, Hannah J. Johnson, Bryant R. England, Cynthia M. Schmidt, Daniel R. Anderson, Jill A. Poole, Tate M. Johnson, Michael J. Duryee, Geoffrey M. Thiele, et al.

    Objective: Substantial progress has been made in understanding the involvement of malondialdehyde-acetaldehyde (MAA) adducts in rheumatoid arthritis (RA) pathogenesis. This systematic review synthesizes current evidence on the role of MAA-modified macromolecules and anti-MAA antibodies in the development, manifestation, and progression of RA. Methods: MEDLINE, EMBASE, the Cochrane Library, Scopus, and SciFinder were searched through May 6, 2025. Studies were screened based on predefined inclusion/exclusion criteria. Study characteristics were extracted, and quality assessments were performed. Results: MAA-modified proteins and MAA-specific autoreactive B cells are elevated in synovial and lung tissues of RA patients. Anti-MAA antibodies are enriched in RA-derived synovial fluids compared to serum. Serum levels of anti-MAA IgG and IgA are increased prior to RA onset, and though not RA-specific, were higher in RA patients than those with other conditions. Anti-MAA antibodies do not cross-react with other autoantibodies, such as anti-citrullinated protein autoantibodies, and can be detected in sera from seronegative RA patients. Elevated anti-MAA antibody levels correlate with progression of joint, lung, and cardiovascular complications, as well as biologic treatment responses. Human and animal studies have begun to elucidate mechanisms by which MAA and anti-MAA antibody might contribute to inflammatory and fibrotic changes in RA. Conclusions: This review provides a comprehensive overview of MAA and its involvement in RA pathogenesis. MAA adducts contribute to loss of immune tolerance and promote both inflammation and fibrosis in RA. Given associations of anti-MAA antibodies with RA disease activity and complications, MAA-related pathways hold promise as both biomarkers and treatment targets in RA. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD4202454490.


  • Open Access

    Citrullinated and Malondialdehyde–Acetaldehyde-Modified Fibrinogen Activates Macrophages and Promotes Coronary Endothelial Cell Inflammation

    by Wenxian Zhou, Hannah J. Johnson, Michael J. Duryee, Nozima Aripova, Engle E. Sharp, Carlos D. Hunter, Kimberley Sinanan, Henry C. Drvol, Mason G. Feely, Tate M. Johnson, et al.

    Individuals with rheumatoid arthritis (RA) face increased cardiovascular mortality due to heart failure (HF) complications. Post-translational modifications, such as citrullination (CIT) and malondialdehyde–acetaldehyde (MAA) adduction, are implicated in RA pathogenesis. However, their role in RA-associated HF is not well understood. This study examines the deposition of MAA and CIT in cardiac tissues of RA-HF patients and investigates how MAA and CIT adducts on fibrinogen (FIB-MAA-CIT) drive crosstalk between macrophages and endothelial cells in vitro. We demonstrated elevated MAA and CIT adducts, strong perivascular MAA-CIT co-localization, and increased perivascular collagen deposition in the myocardium of RA-HF patients compared to non-RA HF controls. Treating human coronary artery endothelial cells (HCAECs) with FIB-MAA-CIT induced upregulation of inflammatory markers including MCP-1, IL-6, ICAM-1, and VCAM-1 compared to unmodified FIB. This response was amplified when HCAECs were treated with cell culture media obtained from FIB-MAA-CIT-stimulated macrophages. FIB-MAA-CIT activation of macrophages engaged NF-κB and p38 signaling pathways and inhibition of these pathways reduced FIB-MAA-CIT-mediated macrophage cytokine secretion and subsequent HCAEC responses. In summary, our findings support a novel mechanism by which endogenously modified proteins drive macrophage–endothelial cell crosstalk, promoting myocardial inflammation. Targeting these post-translational modifications may present novel therapeutic strategies to mitigate HF in RA.


  • Open Access

    Citrullinated and malondialdehyde-acetaldehyde-modified fibrinogen activates macrophages and promotes profibrotic responses in human lung fibroblasts

    by Nozima Aripova, Michael J. Duryee, Wenxian Zhou, Bryant R. England, Carlos D. Hunter, Lauren E. Klingemann, Nigina Aripova, Amy J. Nelson, Dawn Katafiasz, Kristina L. Bailey, et al.

    This report demonstrates that fibrinogen simultaneously harboring two common posttranslational modifications activates macrophages to secrete platelet-derived growth factor (PDGF)-BB and transforming growth factor (TGF)-β. Resulting cross talk between activated macrophages and human lung fibroblasts leads to marked increases in extracellular matrix deposition. These protein modifications are abundant and colocalize in lung tissues from patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD), and the results suggest that agents targeting citrullination and/or malondialdehyde-acetaldehyde (MAA) adduct formation could represent novel therapeutic strategies.


  • Central nervous system complications of human immunodeficiency virus infection

    by Wenxian Zhou, Shaurav Bhattarai, Roshan Sapkota, Andre M. Santamaria, Howard Eliot Gendelman

  • Overexpression of Central ACE2 (Angiotensin-Converting Enzyme 2) Attenuates the Pressor Response to Chronic Central Infusion of Ang II (Angiotensin II)

    by Anyun Ma, Lie Gao, Ahmed M. Wafi, Li Yu, Tara Rudebush, Wenxian Zhou, Irving H. Zucker

    We investigated the mechanism by which ACE2 (angiotensin-converting enzyme 2) overexpression alters neurohumoral outflow and central oxidative stress. Nrf2 (nuclear factor [erythroid-derived 2]-like 2) is a master antioxidant transcription factor that regulates cytoprotective and antioxidant genes. We hypothesized that upregulation of central ACE2 inhibits the pressor response to Ang II (angiotensin II) by reducing reactive oxygen species through a Nrf2/antioxidant enzyme–mediated mechanism in the rostral ventrolateral medulla. Synapsin human Angiotensin Converting Enzyme 2 positive (SynhACE2 +/+ ) mice and their littermate controls synhACE2 −/− were used to evaluate the consequence of intracerebroventricular infusion of Ang II. In control mice, Ang II infusion evoked a significant increase in blood pressure and norepinephrine excretion, along with polydipsia and polyuria. The pressor effect of central Ang II was completely blocked in synhACE2 +/+ mice. Polydipsia, norepinephrine excretion, and markers of oxidative stress in response to central Ang II were also reduced in synhACE2 +/+ mice. The MasR (Mas receptor) agonist Ang 1–7 and blocker A779 had no effects on blood pressure. synhACE2 +/+ mice showed enhanced expression of Nrf2 in the rostral ventrolateral medulla which was blunted following Ang II infusion. Ang II evoked nuclear translocation of Nrf2 in cultured Neuro 2A (N2A) cells. In synhACE2 −/− mice, the central Ang II pressor response was attenuated by simultaneous intracerebroventricular infusion of the Nrf2 activator sulforaphane; blood pressure was enhanced by knockdown of Nrf2 in the rostral ventrolateral medulla in Nrf2 floxed (Nrf2 f/f ) mice. These data suggest that the hypertensive effects of intracerebroventricular Ang II are attenuated by selective overexpression of brain synhACE2 and may be mediated by Nrf2-upregulated antioxidant enzymes in the rostral ventrolateral medulla.